Qwest Corp 7 % Notes 2012-1.4.52 Called for red.on 04.09.18 at USD 25 (CTX)

25.26
NYSE
Prev Close 25.26
Day Low/High 0.00 / 0.00
52 Wk Low/High 22.86 / 25.30
Exchange NYSE
Div & Yield N.A. (N.A)

Latest News

Crescita Therapeutics Engages Bristol Capital To Provide Investor Relations And Communications Services

Crescita Therapeutics Engages Bristol Capital To Provide Investor Relations And Communications Services

LAVAL, QC, May 29, 2019 /PRNewswire/ - Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (Crescita or the Company), a Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the...

Crescita Therapeutics Announces The Results Of Its Annual General And Special Meeting Of Shareholders

Crescita Therapeutics Announces The Results Of Its Annual General And Special Meeting Of Shareholders

LAVAL, QC, May 15, 2019 /PRNewswire/ - Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (Crescita or the Company), a commercial dermatology company with a portfolio of non-prescription skincare and prescription drug products for the treatment and...

Crescita Therapeutics Reports 2019 First Quarter Results

Crescita Therapeutics Reports 2019 First Quarter Results

Year-over-Year Revenue Growth of 16.4%Positive Adjusted EBITDA for Third Consecutive Quarter And Generates $2.

Crescita Therapeutics Strengthens Leadership Team With New Vice-President In Aesthetic And Cosmeceutical Business Unit

Crescita Therapeutics Strengthens Leadership Team With New Vice-President In Aesthetic And Cosmeceutical Business Unit

LAVAL, QC, May 7, 2019 /PRNewswire/ - Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (Crescita or the Company), a Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the...

Crescita Therapeutics Signs Pliaglis® Out-Licensing Agreement With Cantabria Labs For €2.5M Upfront After Reacquiring Rest-of-World Rights

Crescita Therapeutics Signs Pliaglis® Out-Licensing Agreement With Cantabria Labs For €2.5M Upfront After Reacquiring Rest-of-World Rights

LAVAL, QC, April 25, 2019 /PRNewswire/ - Crescita Therapeutics Inc. ("Crescita" or the "Company") (TSX: CTX and OTC US: CRRTF), a Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products...

Crescita Therapeutics To Present At The 2019 Bloom Burton & Co. Healthcare Investor Conference In Toronto

Crescita Therapeutics To Present At The 2019 Bloom Burton & Co. Healthcare Investor Conference In Toronto

LAVAL, QC, April 17, 2019 /PRNewswire/ - Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (Crescita or the Company), a Canadian commercial dermatology company, is pleased to announce that its President and CEO, Serge Verreault will be presenting at...

Crescita Therapeutics Reports Fourth Quarter And Fiscal 2018 Results Record Annual Revenue Of $16.6M And Adjusted EBITDA Of $1.5M Strong Royalties And Sales Milestones

Crescita Therapeutics Reports Fourth Quarter And Fiscal 2018 Results Record Annual Revenue Of $16.6M And Adjusted EBITDA Of $1.5M Strong Royalties And Sales Milestones

LAVAL, QC, March 21, 2019 /PRNewswire/ - Crescita Therapeutics Inc. ( TSX: CTX) (Crescita or the Company), a commercial dermatology company with a portfolio of non-prescription skincare and prescription drug products for the treatment and care of skin...

Crescita Therapeutics Inc.™ And Tetra Natural Health Collaborate To Enhance Transdermal Delivery Of Beta-Caryophyllene In Tetra's Dermatology Product Portfolio

Crescita Therapeutics Inc.™ And Tetra Natural Health Collaborate To Enhance Transdermal Delivery Of Beta-Caryophyllene In Tetra's Dermatology Product Portfolio

LAVAL, QC, and ORLEANS, ON, Feb. 4, 2019 /PRNewswire/ - Crescita Therapeutics Inc.

PulteGroup 3Q Loss Widens On Charges, Tops Street

Homebuilder PulteGroup's 3rd-quarter loss widens on charges, new orders drop 12 percent

Standard & Poor's Lowers Ratings On PulteGroup

Standard & Poor's Lowers Ratings On PulteGroup

S&P lowers ratings on homebuilder PulteGroup, sees weak earnings into 2011 on soft home sales

Homebuilder PulteGroup Returns To Profit In 2Q

Homebuilder PulteGroup posts profit in 2nd quarter ahead of expiration of tax credits

Earnings Preview: PulteGroup

Homebuilder PulteGroup expected to post a penny loss in 2nd-qtr

Pulte Pares 1Q Loss And Now Expects Profit In 2010

Pulte posts narrower loss on smaller charges, expects to report a profit in 2010

Earnings Preview: PulteGroup

Homebuilder PulteGroup expected to report loss for first quarter

PulteGroup CEO's '09 Compensation Essentially Flat

CEO of homebuilder PulteGroup received 2009 pay valued at $5.86 million, flat versus 2008

Housing Data Points To Rocky Rebound

Housing Data Points To Rocky Rebound

Home sales up, but housing recovery likely to be rocky, uneven

Weak Home Building A Drag On Economic Recovery

Weak Home Building A Drag On Economic Recovery

Weak home construction weighing down economic rebound; consumer inflation remains tame

Looking For Land In All The Right Places

Looking For Land In All The Right Places

Land market heats up again as homebuilders vie for property in promising markets

Pulte Homes, Merck, Garmin Are Big Movers

Pulte Homes, Merck, Garmin, Kraft, Ambac Financial are among big market movers Wednesday

Earnings Roundup: Pulte Homes, Ameristar Casinos

Earnings Roundup: Pulte Homes, Ameristar Casinos

Earnings roundup: Pulte Homes posts loss, but new orders rise; Ameristar Casinos profit rises

Pulte Homes Posts $361.4M Loss For Q3

Pulte Homes Posts $361.4M Loss For Q3

Homebuilder Pulte Homes loses $361.4 million in 3rd-qtr following Centex acquisition

Earnings Preview: Pulte Homes To Post 3Q Results

Homebuilder Pulte Homes to post 3rd-quarter results ahead of tax credit expiration

Homebuilder Shares Slide As Analyst Cuts Estimates

Homebuilder Shares Slide As Analyst Cuts Estimates

Shares of homebuilders slide as analyst cuts estimates, expects housing market to remain weak

Pulte Buys Back $1.5 Billion In Debt

Pulte Buys Back $1.5 Billion In Debt

Pulte buys back $1.5 billion in debt from Centex deal

Pulte Announces Early Tender Offer Results

Pulte Announces Early Tender Offer Results

Pulte announces early tender offer results for $1.5 billion in debt

Fitch Upgrades Centex Ratings In Line With Pulte's

Fitch Upgrades Centex Ratings In Line With Pulte's

Fitch upgrades Centex ratings in line with those at Pulte, which closed purchase of Centex

GameStop CFO To Retire Next Year

GameStop names Catherine Smith to be CFO upon David Carlson's retirement next March

Summary Box: Pulte Takeover Of Centex Gets OK

Summary Box: Pulte Takeover Of Centex Gets OK

Summary Box: Shareholders pave way for Pulte Homes takeover of rival builder Centex